Mobile Site ›

Test Catalog

Test ID: MPS6S    
Mucopolysaccharidosis VI, Full Gene Analysis

Useful For Suggests clinical disorders or settings where the test may be helpful

Identifying mutations within the ARSB gene


Confirmation of a diagnosis of mucopolysaccharidosis type VI


Carrier testing, when there is a family history of mucopolysaccharidosis type VI, but disease-causing mutations have not been previously identified

Genetics Test Information Provides information that may help with selection of the correct test or proper submission of the test request

Testing includes full gene sequencing of the ARSB gene.

Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Mucopolysaccharidosis type VI (MPS-VI), also known as Maroteaux-Lamy syndrome, is an autosomal recessive condition that is caused by mutations in the ARSB gene and is characterized by reduced or absent activity of the arylsulfatase B enzyme. This test screens for mutations in all 8 exons of the ARSB gene.


The clinical features and severity of symptoms of Maroteaux-Lamy are widely variable. Typically it is characterized by short stature, dysostosis multiplex, facial dysmorphism, stiff joints, hepatosplenomegaly, corneal clouding, cardiac defects, and usually normal intelligence. With a rapidly progressing form of MPS-VI, onset occurs before 2 to 3 years of age with death typically occurring in the second to third decade. With a slowly progressing form of MPS-VI, a diagnosis usually occurs after 5 years of age but may not occur until the second or third decade.  


The recommended first-tier test for MPS-VI is biochemical testing that measures arylsulfatase B enzyme activity in fibroblasts (ARSB / Arylsulfatase B, Fibroblasts). Individuals with decreased or absent enzyme activity are more likely to have 2 identifiable mutations in the ARSB gene by molecular genetic testing. However, enzymatic testing is not reliable to detect carriers.

Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

An interpretive report will be provided.

Interpretation Provides information to assist in interpretation of the test results

An interpretive report will be provided.

Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

A small percentage of individuals who are carriers or have a diagnosis of mucopolysaccharidosis type VI (MPS-VI) may have a mutation that is not identified by this method (eg, large genomic deletions, promoter mutations). The absence of a mutation, therefore, does not eliminate the possibility of positive carrier status or the diagnosis of MPS-VI. The preferred approach to carrier testing is to first document the presence of an ARSB gene mutation in an affected family member.


In some cases, DNA alterations of undetermined significance may be identified.


Rare polymorphisms exist that could lead to false-negative or false-positive results. If results obtained do not match the clinical findings, additional testing should be considered.


A previous bone marrow transplant from an allogenic donor will interfere with testing. Call Mayo Medical Laboratories for instructions for testing patients who have received a bone marrow transplant.


Test results should be interpreted in the context of clinical findings, family history, and other laboratory data. Errors in our interpretation of results may occur if information given is inaccurate or incomplete.

Clinical Reference Provides recommendations for further in-depth reading of a clinical nature

1. Litjens T, Hopwood JJ: Mucopolysaccharidosis type VI: Structural and clinical implications of mutations in N-acetylgalactosamine-4-sulfatase. Hum Mutat 2001;18(4):282-295

2. Richards CS, Bale S, Bellissimo DB, et al: ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007. Genet Med 2008:10(4):294-300

3. Valayannopoulos V, Nicely H, Harmatz P, et al: Mucopolysaccharidosis VI. Orphanet J Rare Dis 2010;5:5

Special Instructions and Forms Describes specimen collection and preparation information, test algorithms, and other information pertinent to test. Also includes pertinent information and consent forms to be used when requesting a particular test